DGI:Abdominelle Infektionen/Therapie/Erregerspezifische Therapie: Unterschied zwischen den Versionen
Die Seite wurde neu angelegt: „ Eine Anpassung der antiinfektiven Therapie entsprechend des nachgewiesenen Erregerspektrums sollte so früh wie möglich erfolgen. Tabelle 7 zeigt orientieren…“ |
Keine Bearbeitungszusammenfassung |
||
| Zeile 5: | Zeile 5: | ||
{| class="wikitable MsoTableGrid" style="width:100%;" border="1" cellspacing="0" cellpadding="0" width="652" | {| class="wikitable MsoTableGrid" style="width:100%;" border="1" cellspacing="0" cellpadding="0" width="652" | ||
|+ | |+Tabelle 7: Spektren verfügbarer Antiinfektiva | ||
| style="width:148.8pt;" width="198" |< | | style="width:148.8pt;" width="198" |<small>Präparat</small> | ||
| colspan="16" style="width:340.0pt;" width="453" |< | | colspan="16" style="width:340.0pt;" width="453" |<small>Erreger</small> | ||
| style="" width="1" | | | style="" width="1" | | ||
|- style="height:275.8ptpx;" | |- style="height:275.8ptpx;" | ||
| style="width:148.8pt;" width="198" valign="top" | | | style="width:148.8pt;" width="198" valign="top" | | ||
| style="width:21.25pt;" width="28" | | | style="width:21.25pt;" width="28" |<small>P. aerugionsa WT</small> | ||
| style="width:21.25pt;" width="28" | | | style="width:21.25pt;" width="28" |<small>P. aeruginosa AmpC</small> | ||
| style="width:21.25pt;" width="28" | | | style="width:21.25pt;" width="28" |<small>P. aeruginosa Porinverlust (oprD-loss)</small> | ||
| style="width:21.25pt;" width="28" | | | style="width:21.25pt;" width="28" |<small>P. aeruginosa Effluxpumpen</small> | ||
| style="width:21.25pt;" width="28" | | | style="width:21.25pt;" width="28" |<small>P. aeruginosa Carbapenem-R (Ø Carbapenemase)</small> | ||
| style="width:21.4pt;" width="29" | | | style="width:21.4pt;" width="29" |<small>P. aeruginosa MBL+</small> | ||
| style="width:21.25pt;" width="28" |< | | style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae WT</small> | ||
| style="width:21.25pt;" width="28" |< | | style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae ESBL+</small> | ||
| style="width:21.25pt;" width="28" |< | | style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae OXA-48-like+</small> | ||
| style="width:21.25pt;" width="28" |< | | style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae KPC</small> | ||
| style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae Carbapenem-R (Ø Carbapenemase)</small> | |||
| style="width:21.25pt;" width="28" | | | style="width:21.45pt;" width="29" |<small>Entero-bacteriaceae MBL+ (VIM,IMP,NDM)</small> | ||
| style="width:21.45pt;" width="29" | | | style="width:21.25pt;" width="28" |<small>Acinetobacter baumannii WT</small> | ||
| style="width:21.25pt;" width="28" |< | | style="width:21.25pt;" width="28" |<small>Acinetobacter baumannii Carbapenem-R</small> | ||
| style="width:21.25pt;" width="28" |< | | style="width:21.25pt;" width="28" |<small>Steno-trophomonas maltophilia WT</small> | ||
| style="width:21.25pt;" width="28" | | | colspan="2" style="width:21.4pt;" width="29" |<small>Steno-trophomonas maltophilia Carbapenem-R</small> | ||
| colspan="2" style="width:21.4pt;" width="29" | | |||
|- style="height:17.0ptpx;" | |- style="height:17.0ptpx;" | ||
| style="width:148.8pt;" width="198" |Ceftazidim/ Avibactam | | style="width:148.8pt;" width="198" |<small>Ceftazidim/ Avibactam</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-white-bg" width="28" | | | style="width:21.25pt;" class="col-white-bg" width="28" | | ||
| Zeile 47: | Zeile 46: | ||
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" | | | colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" | | ||
|- style="height:17.0ptpx;" | |- style="height:17.0ptpx;" | ||
| style="width:148.8pt;" width="198" |< | | style="width:148.8pt;" width="198" |<small>Ceftolozan/ Tazobactam</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| Zeile 65: | Zeile 64: | ||
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" | | | colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" | | ||
|- style="height:17.0ptpx;" | |- style="height:17.0ptpx;" | ||
| style="width:148.8pt;" width="198" |< | | style="width:148.8pt;" width="198" |<small>Imipenem/ Relebactam</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| Zeile 83: | Zeile 82: | ||
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" | | | colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" | | ||
|- style="height:17.0ptpx;" | |- style="height:17.0ptpx;" | ||
| style="width:148.8pt;" width="198" |< | | style="width:148.8pt;" width="198" |<small>Meropenem/ Varbobactam</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| Zeile 101: | Zeile 100: | ||
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" | | | colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" | | ||
|- style="height:17.0ptpx;" | |- style="height:17.0ptpx;" | ||
| style="width:148.8pt;" width="198" |< | | style="width:148.8pt;" width="198" |<small>Colisitin</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| Zeile 119: | Zeile 118: | ||
| colspan="2" style="width:21.4pt;" class="col-white-bg" width="29" | | | colspan="2" style="width:21.4pt;" class="col-white-bg" width="29" | | ||
|- style="height:17.0ptpx;" | |- style="height:17.0ptpx;" | ||
| style="width:148.8pt;" width="198" |< | | style="width:148.8pt;" width="198" |<small>Cefiderocol</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| Zeile 137: | Zeile 136: | ||
| colspan="2" style="width:21.4pt;" class="col-green-bg" width="29" | | | colspan="2" style="width:21.4pt;" class="col-green-bg" width="29" | | ||
|- style="height:17.0ptpx;" | |- style="height:17.0ptpx;" | ||
| style="width:148.8pt;" width="198" |< | | style="width:148.8pt;" width="198" |<small>Ceftobiprol</small> | ||
| style="width:21.25pt;" class="col-red-bg" width="28" | | | style="width:21.25pt;" class="col-red-bg" width="28" | | ||
| style="width:21.25pt;" class="col-red-bg" width="28" | | | style="width:21.25pt;" class="col-red-bg" width="28" | | ||
| Zeile 157: | Zeile 156: | ||
<br /> | <br /> | ||
{| class="wikitable sortable mw-collapsible MsoTableGrid" style="width:100%;" border="1" cellspacing="0" cellpadding="0" width="369" | {| class="wikitable sortable mw-collapsible MsoTableGrid" style="width:100%;" border="1" cellspacing="0" cellpadding="0" width="369" | ||
|+ | |+Tabelle 8: Erregerspezifische Antimykotikatherapie bei IAI | ||
| style="width:148.8pt;" width="198" |<small>Präparat</small> | |||
| colspan="6" style="width:127.6pt;" width="170" |<small>Erreger</small> | |||
| style="width:148.8pt;" width="198" |< | |||
| colspan="6" style="width:127.6pt;" width="170" |Erreger | |||
|- style="height:117.15ptpx;" | |- style="height:117.15ptpx;" | ||
| style="width:148.8pt;" width="198" valign="top" | | | style="width:148.8pt;" width="198" valign="top" | | ||
| style="width:21.25pt;" width="28" valign="top" | | | style="width:21.25pt;" width="28" valign="top" |<small>Candida albicans</small> | ||
| style="width:21.25pt;" width="28" valign="top" | | | style="width:21.25pt;" width="28" valign="top" |<small>Candida glabrata</small> | ||
| style="width:21.25pt;" width="28" valign="top" | | | style="width:21.25pt;" width="28" valign="top" |<small>Candida parapsilosis</small> | ||
| style="width:21.25pt;" width="28" valign="top" | | | style="width:21.25pt;" width="28" valign="top" |<small>Candida krusei</small> | ||
| style="width:21.25pt;" width="28" valign="top" | | | style="width:21.25pt;" width="28" valign="top" |<small>Aspergillus fumigatus</small> | ||
| style="width:21.35pt;" width="28" valign="top" | | | style="width:21.35pt;" width="28" valign="top" |<small>Aspergillus niger</small> | ||
|- style="height:31.2ptpx;" | |- style="height:31.2ptpx;" | ||
| style="width:148.8pt;" width="198" valign="top" |< | | style="width:148.8pt;" width="198" valign="top" |<small>Fluconazol</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-white-bg" width="28" | | | style="width:21.25pt;" class="col-white-bg" width="28" | | ||
| Zeile 181: | Zeile 176: | ||
| style="width:21.35pt;" class="col-red-bg" width="28" | | | style="width:21.35pt;" class="col-red-bg" width="28" | | ||
|- style="height:31.2ptpx;" | |- style="height:31.2ptpx;" | ||
| style="width:148.8pt;" width="198" valign="top" |< | | style="width:148.8pt;" width="198" valign="top" |<small>Voriconazol</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-blue-light-bg" width="28" | | | style="width:21.25pt;" class="col-blue-light-bg" width="28" | | ||
| Zeile 189: | Zeile 184: | ||
| style="width:21.35pt;" class="col-green-bg" width="28" | | | style="width:21.35pt;" class="col-green-bg" width="28" | | ||
|- style="height:31.2ptpx;" | |- style="height:31.2ptpx;" | ||
| style="width:148.8pt;" width="198" valign="top" |< | | style="width:148.8pt;" width="198" valign="top" |<small>Isavuconazol</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" valign="top" | | | style="width:21.25pt;" class="col-green-bg" width="28" valign="top" | | ||
| style="width:21.25pt;" class="col-blue-light-bg" width="28" valign="top" | | | style="width:21.25pt;" class="col-blue-light-bg" width="28" valign="top" | | ||
| Zeile 197: | Zeile 192: | ||
| style="width:21.35pt;" class="col-green-bg" width="28" valign="top" | | | style="width:21.35pt;" class="col-green-bg" width="28" valign="top" | | ||
|- style="height:31.2ptpx;" | |- style="height:31.2ptpx;" | ||
| style="width:148.8pt;" width="198" valign="top" |< | | style="width:148.8pt;" width="198" valign="top" |<small>Caspofungin</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| Zeile 205: | Zeile 200: | ||
| style="width:21.35pt;" class="col-green-bg" width="28" | | | style="width:21.35pt;" class="col-green-bg" width="28" | | ||
|- style="height:31.2ptpx;" | |- style="height:31.2ptpx;" | ||
| style="width:148.8pt;" width="198" valign="top" |< | | style="width:148.8pt;" width="198" valign="top" |<small>Anidulafungin</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| Zeile 213: | Zeile 208: | ||
| style="width:21.35pt;" class="col-green-bg" width="28" | | | style="width:21.35pt;" class="col-green-bg" width="28" | | ||
|- style="height:17.0ptpx;" | |- style="height:17.0ptpx;" | ||
| style="width:148.8pt;" width="198" |< | | style="width:148.8pt;" width="198" |<small>Micafungin</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| Zeile 221: | Zeile 216: | ||
| style="width:21.35pt;" class="col-green-bg" width="28" | | | style="width:21.35pt;" class="col-green-bg" width="28" | | ||
|- style="height:17.0ptpx;" | |- style="height:17.0ptpx;" | ||
| style="width:148.8pt;" width="198" |< | | style="width:148.8pt;" width="198" |<small>Liposomales Amphotericin B</small> | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
| style="width:21.25pt;" class="col-green-bg" width="28" | | | style="width:21.25pt;" class="col-green-bg" width="28" | | ||
Version vom 9. Juni 2021, 05:12 Uhr
Eine Anpassung der antiinfektiven Therapie entsprechend des nachgewiesenen Erregerspektrums sollte so früh wie möglich erfolgen. Tabelle 7 zeigt orientierend die aktuell neu verfügbaren Antiinfektiva für die Therapie von IAI durch MRE. Eine entsprechende Therapie sollte aber immer unter Berücksichtigung des aktuellen Antibiogrammes ausgewählt werden. Tabelle 8 gibt einen Überblick zur erregerspezifischen antimykotischen Therapie.
Auch im Setting der erregerspezifischen Therapie wird die Konsequenz eines Nachweises von Candida spp. und/oder Enterokokken aus dem Bauchraum oder aus Drainagesekreten kontrovers diskutiert. Der Nachweis beider Erregergruppen ist häufig das Ergebnis einer vorhergehenden intensiven Antibiotikaexposition und entsprechenden Selektion im Setting der tertiären Peritonitis. Bisherige Studien konnten zwar zeigen, dass ein entsprechender Nachweis mit einer ungünstigen Prognose assoziiert ist. Interventionelle Studien haben jedoch keine Verbesserung der Prognose basierend auf einer auf Enterokokken bzw. Candida spp. angepassten Therapie zeigen können. Daher bleibt unklar, ob der Nachweis dieser Erreger in diesem Setting tatsächlich eine klinische Relevanz hat, die über die eines Biomarkers für eine ungünstige Prognose hinausgeht. Aus diesem Grunde kann bei einem klinisch stabilen Patienten ohne aktuelle Hinweise einer floriden Infektion in Einzelfällen auch eine zuwartende Strategie verfolgt werden.
| Präparat | Erreger | ||||||||||||||||
| P. aerugionsa WT | P. aeruginosa AmpC | P. aeruginosa Porinverlust (oprD-loss) | P. aeruginosa Effluxpumpen | P. aeruginosa Carbapenem-R (Ø Carbapenemase) | P. aeruginosa MBL+ | Entero-bacteriaceae WT | Entero-bacteriaceae ESBL+ | Entero-bacteriaceae OXA-48-like+ | Entero-bacteriaceae KPC | Entero-bacteriaceae Carbapenem-R (Ø Carbapenemase) | Entero-bacteriaceae MBL+ (VIM,IMP,NDM) | Acinetobacter baumannii WT | Acinetobacter baumannii Carbapenem-R | Steno-trophomonas maltophilia WT | Steno-trophomonas maltophilia Carbapenem-R | ||
| Ceftazidim/ Avibactam | |||||||||||||||||
| Ceftolozan/ Tazobactam | |||||||||||||||||
| Imipenem/ Relebactam | |||||||||||||||||
| Meropenem/ Varbobactam | |||||||||||||||||
| Colisitin | |||||||||||||||||
| Cefiderocol | |||||||||||||||||
| Ceftobiprol | |||||||||||||||||
| Präparat | Erreger | |||||
| Candida albicans | Candida glabrata | Candida parapsilosis | Candida krusei | Aspergillus fumigatus | Aspergillus niger | |
| Fluconazol | ||||||
| Voriconazol | ||||||
| Isavuconazol | ||||||
| Caspofungin | ||||||
| Anidulafungin | ||||||
| Micafungin | ||||||
| Liposomales Amphotericin B | ||||||